💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Merck withdraws European marketing application for Keytruda in first-line NSCLC

Published 10/27/2017, 04:33 PM
© Reuters.  Merck withdraws European marketing application for Keytruda in first-line NSCLC
MRK
-
  • Merck (NYSE:MRK) shareholders now know the main reason behind today's selloff. After the close, it announced that it has withdrawn its marketing application in Europe seeking approval to use Keytruda (pembrolizumab), in combination with pemetrexed and carboplatin, for the first-line treatment of nonsquamous non-small cell lung cancer (NSCLC), a large potential market being hotly pursued by a list of competitors.
  • The company says it is "confident" in the clinical data supporting the application, generated in the KEYNOTE-021 study, Cohort G1, but apparently not overconfident considering the withdrawal.
  • Topline data from the KEYNOTE-189 study, also in first-line NSCLC, is being anxiously awaited by investors.
  • Shares are off a fraction after hours on robust volume.
  • Previously: Merck announces follow-up data with Merck’s KEYTRUDA (June 3)
  • Now read: Why The Anti-Amyloid Approach To Alzheimer's Disease Has Failed


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.